Handok Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Sep 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 14, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,728,514 | Transdermal Preparations Containing Hydrophoic Non-Steroidal Anti-Inflammatory Drugs In force · High confidence | In force | High confidence | |
| US 9,403,831 | Novel Triazolopyrazine Derivative and Use Thereof In force · High confidence | In force | High confidence | |
| US 9,701,681 | Fused ring heteroaryl compounds and their use as Trk inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,196,396 | Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,427,186 | Method for treating growth hormone deficiency employing hGH fusion protein In force · From the USPTO record | In force | From the USPTO record | |
| US 12,233,113 | Pharmaceutical composition comprising recombinant hGH for the treatment of growth hormone deficiency In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 6: 1 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending